Semaglutide vs Retatrutide: Research Comparison | Regena

Semaglutide is a selective GLP-1 receptor agonist with no meaningful GIP or glucagon receptor activity — the reference single-axis incretin compound.

Retatrutide is a balanced triple agonist at the GLP-1, GIP and glucagon receptors, engineered as the follow-on to the dual GLP-1 / GIP agonist tirzepatide. The added GIP and glucagon arms are the headline pharmacological distinctions.

Semaglutide gives a clean GLP-1-only receptor arm — the standard reference for isolating GLP-1 signalling from other incretin-axis effects.

Retatrutide adds substantial GIP and glucagon receptor activity on top of the GLP-1 signal, which in published phase 2 research has been associated with stronger hepatic-lipid oxidation and resting-energy-expenditure signals than GLP-1 activation alone.

Semaglutide has an approximate half-life of 165 hours (~7 days). Retatrutide has an approximate half-life of ~6 days. Both support weekly-cadence research protocols and both are stable to DPP-4 degradation thanks to fatty-acid acylation.

The pharmacokinetic profiles are close enough that matched weekly-cadence comparator studies pair cleanly without cadence-mismatch confounds.

Semaglutide is the reference GLP-1 arm for any comparator design where the added incretin arms of tirzepatide or retatrutide are the experimental variable being isolated.

Retatrutide is the reference triple-agonist arm for research protocols where the glucagon arm — hepatic-lipid oxidation, resting-energy-expenditure — is central to the experimental design.

Both Semaglutide and Retatrutide ship from Regena only after independent third-party verification — Janoshik Analytical is the default verifier, with orthogonal independent laboratories used when batch chemistry calls for confirmation by a second method. Minimum release specification is ≥99.0% HPLC main-peak purity with matching mass-spectrometry molecular weight and water content within the published specification for the compound.

Batch COAs for both compounds are published on the Regena lab reports page so a research-peptide buyer can audit the analytical detail before purchase. The /trust/how-to-read-a-coa reference walks through every field on a modern Regena COA.

Both compounds ship lyophilised under nitrogen. Hold the unopened vial at 2–8 °C; freeze at −20 °C for long-term storage. Reconstitution with bacteriostatic water (0.9% benzyl alcohol) supports a 28-day in-use stability window under refrigeration for both compounds.

Aliquot before any freeze. The single most common cause of measurable potency loss in research peptides is repeat freeze-thaw cycling — both Semaglutide and Retatrutide benefit from single-thaw aliquot workflows. Vortex gently, never shake aggressively, and keep reconstituted vials away from direct light. The /research/compound-storage-guide reference covers the per-compound stability windows in detail.

Researchers choose semaglutide when the protocol requires clean GLP-1-only receptor activation or a reference single-axis arm. Researchers choose retatrutide when the protocol requires balanced triple-receptor activation. Matched semaglutide + retatrutide arms are one of the most common comparator designs for isolating the contribution of the GIP and glucagon receptor arms above the GLP-1 baseline.

For multi-compound comparator studies, the Regena consultations team will reserve matched-batch inventory of both Semaglutide and Retatrutide against a project timeline so the experimental panel is sourced under a single analytical specification window.

Both Semaglutide and Retatrutide are supplied strictly for in-vitro and preclinical research use. They are not medicines, are not approved for human consumption in Spain, the United Kingdom, the European Union or the United States, and are not dispensed against a prescription. The research-use declaration ships with every package alongside the independent third-party COA.

Comparison pages on the Regena site exist for laboratory-research reference. Nothing on this page constitutes a recommendation for human use of either compound.